Cash backing of nearly $9m equates 9c plus. Asset value of 3c per share. 12c minimum with growth prospects with the same TXN management. Verdict: undervalued.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%